Outcome of Liver Transplant Patients With Preformed Donor‐Specific Anti–Human Leukocyte Antigen Antibodies

Arnaud Del Bello, Martine Neau‐Cransac, Laurence Lavayssiere, Valérie Dubois, Nicolas Congy‐Jolivet, Jonathan Visentin, Marie Danjoux, Brigitte Le Bail, Valérie Hervieu, Olivier Boillot, Teresa Antonini, Nassim Kamar, Jérôme Dumortier – 14 October 2019 – After liver transplantation (LT), the role of preformed donor‐specific anti–human leukocyte antigen antibodies (pDSAs) remains incompletely understood. We conducted a retrospective, case‐control analysis to determine the impact of pDSAs after LT in 3 French transplant centers (Bordeaux, Lyon, and Toulouse).

Differential Impact of Age Among Liver Transplant Candidates With and Without Hepatocellular Carcinoma

Giuseppe Cullaro, Jessica B. Rubin, Neil Mehta, Jennifer C. Lai – 14 October 2019 – Hepatocellular carcinoma (HCC) is the fastest‐rising cause of cancer‐related mortality in the United States and is a leading indication for liver transplantation (LT). Changes have been noted in the age of the population with chronic liver disease, but how this change affects patients with HCC is unknown. This study aims to characterize trends and transplant‐associated outcomes among patients ≥65 years old listed for LT with HCC.

Activation of WNT/Beta‐Catenin Signaling and Regulation of the Farnesoid X Receptor/Beta‐Catenin Complex After Murine Bile Duct Ligation

Rong Zhang, Toshimasa Nakao, Jing Luo, Yuhua Xue, Pamela Cornuet, Michael Oertel, Karis Kosar, Sucha Singh, Kari Nejak‐Bowen – 14 October 2019 – We have recently shown that loss of β‐catenin prevents the development of cholestatic liver injury and fibrosis after bile duct ligation (BDL) due to loss of the inhibitory farnesoid X receptor (FXR)/β‐catenin complex, which results in decreased hepatic bile acids (BAs) through activation of FXR.

Nonalcoholic Steatohepatitis After Liver Transplantation

Thomas G. Cotter, Michael Charlton – 14 October 2019 – Currently, nonalcoholic steatohepatitis (NASH) is the second leading indication for liver transplantation (LT), behind alcohol‐related liver disease. After transplant, both recurrent and de novo nonalcoholic fatty liver disease are common; however, recurrence rates of NASH and advanced fibrosis are low. Identification of high‐risk groups and optimizing treatment of metabolic comorbidities both before and after LT is paramount to maintaining a healthy allograft, especially with the additional consequences of longterm immunosuppression.

Subscribe to